Two Sigma Advisers
CADX

Two Sigma Advisers’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Two Sigma Advisers’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-12,576
Closed -$113K – 2729
2013
Q4 		$113K Buy
+12,576
New +$90.8K ﹤0.01% 2203

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Two Sigma Advisers's CADX Position: Q1 2014 in Review

Two Sigma Advisers sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 12,576 shares — an estimated $113K sold.

Two Sigma Advisers first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $113K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Two Sigma Advisers reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Two Sigma Advisers sold 12,576 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $113K.
  • Two Sigma Advisers first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
  • Two Sigma Advisers's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $113K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Two Sigma Advisers's 13F filing for Q1 2014, filed 15 May 2014.